About
Webinar
Agenda
  • 5.30pm : Registration
  • 6:00pm : Opening Remark by Richard Abela
  • 6:05pm : Welcome and Introduction (Chair) by Emeritus Prof Dr Chan Siew Pheng
  • 6.10pm : Role of Oral Semaglutide across the spectrum of Diabetes Journey by Prof Dr Norlela Sukor, Dr Siti Harnida Md Isa, Dr Hew Fen Lee
  • Panel Case Discussion:
  • Newly diagnosed T2D as first-line-monotherapy
  • T2D uncontrolled on oral antidiabetic drug
  • Optimizing outcome for patients on insulin
  • 6:50pm : Efficacy and Safety in patients with T2D and renal impairment by Dr Yew Shiong Shiong, Dr Tan Li Ping, Dr Ng Eng Khim
  • Panel Case Discussion
  • Optimizing outcomes for DKD patients
  • Obese DKD patients
  • Safety and Efficacy in relatively poor eGFR
  • 7:30pm : Effects on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes by Dr Ng Wai Kiat, Dr Emily Tan Lay Koon
  • Panel Case Discussion
  • Mode of Action: GLP-1RA and the Heart
  • Optimising outcomes in High CV Risk T2D Patients
  • Post myocardial infarction patient
  • 8:10pm : Closing Remarks
Presenters
1597456957-2c8f77e3042750b9
Novo Nordisk
Y
Alof KL
AV Tech
J
TECH Penang
Tech
N
Tech Johor
Tech
A
Tech Sabah
Tech
L
TECH PERAK
Tech
N
TECH PAHANG
TECH
N
TECH KELANTAN
TECH
Register To Watch Recording
First Name*
Last Name*
Email Address*
Salutation*
NRIC (Required for Malaysian CPD Accreditation)*
Mobile No.*
Place of Practice*
Specialty*
MMC / MCR No. (Please put NA if not application)*
State*
Personal Data Protection Act
“PRIVACY NOTICE FOR PARTICIPANTS IN THE NOVO NORDISK MEDICAL EDUCATION EVENT. Novo Nordisk shall ensure that the collection, use and disclosure of your personal data is consistent with the requirements under the Personal Data Protection Act 2010 of Malaysia (‘PDPA’), as the case may be. This Privacy Notice (“Privacy Notice”) describes the types of Personal Data (defined below) that Novo Nordisk Pharma (Malaysia) Sdn. Bhd. (“hereinafter referred to as “we” or “us” or “our”) collects about you, the purposes for collecting and using such information, the classes of third parties to whom we may disclose your Personal Data and the choices and means we offer you for limiting its use and disclosure. Your personal data, including without limitation to the personal data that you may have provided us in writing or by request (“Personal Data”), is processed for the purpose of your participation in the Novo Nordisk Medical Education event and also for internal record-keeping via our IO Engage database, marketing and for similar purposes (collectively, “Purpose”). We may also process Personal Data which is considered ‘sensitive’ under the PDPA, including but not limited to Personal Data relating to your health, religion, professional preferences, and philosophical beliefs (collectively, “Sensitive Personal Data”). Personal Data shall therefore include Sensitive Personal Data for the purpose of this Notice. We also wish to inform you that your Personal Data may be disclosed to authorized third parties, such as to our affiliates and/or our legally-appointed service providers, which may be located outside Malaysia (provided that the integrity and security of such information meets the required standards of protection), for reasons relating to the Purpose. Personal Data may also be shared to third party service providers for the purpose of Malaysia CPD point application post-event. It is hereby acknowledged that personal data collected and processed is obtained voluntarily and with your consent. You may request for access to or correction of your Personal Data or withdraw the processing thereof at any time hereafter by submitting such request to us via email: Privacymy@novonordisk.com. Any inquiries or complaints with respect to your Personal Data should also be channelled to us in this manner.
Yes, I have read and understood all of the above terms and agreed to be bound by those terms *
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.